YBX1 and medulloblastoma: Especially notable given its role in very high-risk and treatment-refractory medulloblastoma, was the significant inactivation of the MYC oncoprotein following YB-1 knockdown in the D283 MBGroup3 cell line and medulloblastoma patients with low YB-1 gene expression [3].